Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript
Source: SeekingAlpha
2026-05-19 14:10:47 ET
Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA May 19, 2026 9:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript
Hansa Biopharma AB
NASDAQ: HNSBF
HNSBF Trading
0.0% G/L:
$2.90 Last:
100 Volume:
$2.90 Open:
HNSBF Latest News
September 24, 2025 02:06:00 pm
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
